Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9975 Summers Ridge Road SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.quidelortho.com |
IR: | See website |
Key People | ||
Brian J. Blaser President, Chief Executive Officer | Robert J. Bujarski Interim President, Chief Operating Officer, Executive Vice President | Michael S. Iskra Interim Chief Executive Officer, Executive Vice President, Chief Commercial Officer |
Joseph M. Busky Chief Financial Officer | Michelle A. Hodges Senior Vice President, General Counsel, Corporate Secretary | Werner E. Kroll Senior Vice President - Research and Development | Louise M. Brandy Chief Information Officer |
Business Overview |
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories. |
Financial Overview |
For the fiscal year ended 31 December 2023, Quidelortho Corp revenues decreased 8% to $3B. Net loss totaled $10.1M vs. income of $548.7M. Revenues reflect North America segment decrease of 26% to $1.88B. Net loss reflects Selling, General & Administrative Expens increase of 23% to $601.4M (expense), Term Loan increase from $74.5M to $178.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $9.66 to -$0.15. |
Employees: | 7,100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,090M as of Dec 31, 2023 |
Annual revenue (TTM): | $2,998M as of Dec 31, 2023 |
EBITDA (TTM): | $709.70M as of Dec 31, 2023 |
Net annual income (TTM): | -$10.10M as of Dec 31, 2023 |
Free cash flow (TTM): | $70.90M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $2,247M as of Dec 31, 2023 |
Shares outstanding: | 66,878,683 as of Mar 18, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |